Journal title : Universal Journal of Pharmaceutical Research
Publisher : Society of Pharmaceutical Tecnocrats
Print ISSN : 2831-5235
1.4K Views Reviews Article
The global burden of metabolic disorders, including obesity and type 2 diabetes, necessitates innovative therapeutic strategies. SLU-PP-332, a synthetic agonist of estrogen-related receptor α (ERRα), has emerged as a promising exercise mimetic, demonstrating preclinical efficacy in enhancing mitochondrial biogenesis, insulin sensitivity, and energy expenditure. This brief review synthesizes current knowledge on SLU-PP-332 and related ERRα agonists, highlighting their molecular mechanisms, preclinical outcomes, translational challenges, and ethical considerations. ERRα activation by SLU-PP-332 upregulates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), driving fatty acid oxidation and mimicking exercise-induced metabolic adaptations. However, pan-ERR activity raises concerns about off-target effects such as cardiac hypertrophy and hepatotoxicity. Despite robust preclinical data, clinical translation remains hindered by the absence of human trials and undefined long-term safety. Future research must prioritize isoform-selective agonist design, rigorous clinical validation, and equitable access frameworks.
DOI : https://doi.org/10.22270/ujpr.v10i3.1355
The global endeavor to develop and deploy covid-19 vaccines has underscored both significant scientific progress and enduring disparities in worldwide access. this analysis examine...
Epithelial cells, lining the skin and internal organs, play a crucial role as protective barriers and regulators of substance transport. traditionally, these cells were not conside...
The subjective experience of consciousness, a cornerstone of human existence, is profoundly disrupted in disorders of consciousness (doc) arising from severe brain injuries, spanni...
This is a non-inclusive collection of my published articles....